Literature DB >> 17273135

Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications.

Olivier Levy-Neumand1, François Carniaux, Bruno Bonaz, Aurélie Durand, Xavier Roblin.   

Abstract

OBJECTIVE: To determine whether inaugural prescriptions for proton pump inhibitors (PPI) written by general practitioners in the Grenoble region are in non-compliance with the indications of the French drug marketing authorization.
METHODS: The study was conducted on all inaugural PPI prescriptions written by general practitioners in Grenoble region between March 1 and March 31, 2004. Analyses were performed on a random sample of 600 representative prescriptions. A questionnaire was sent to the general practitioners who had written these prescriptions. There were 255 responses which could be analyzed. RESULT: Among the 19,983 prescriptions for PPIs written in March 2004, 4, 442 (22.8%) were first-time treatments. 85.9% of them were issued by general practitioners. The main reasons for prescription identified in the study sample were the association with other drugs [56.1%; 95%CI 50.0-62.2], gastroesophageal reflux disease [29.4%; 95%CI 23.8-35.0] and dyspepsia [11.4%; 95%CI 7.5-15.3]. The rate of non-compliance with the marketing authorization was 46.3% [95%CI 40.2-52.4], including 20.4% [95%CI 15.5-25.3] for inappropriate medical indications.
CONCLUSION: General practitioners were the principal prescribers of inaugural PPI treatments. Even after excluding prescriptions which were non-compliant because of a regulatory problem, one out of five prescriptions were written for inappropriate medical indications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273135     DOI: 10.1016/s0399-8320(07)89330-4

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  4 in total

1.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

2.  Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.

Authors:  Marion Lassalle; Thien Le Tri; Marc Bardou; Michel Biour; Julien Kirchgesner; Frank Rouby; Nathalie Dumarcet; Mahmoud Zureik; Rosemary Dray-Spira
Journal:  Eur J Clin Pharmacol       Date:  2019-12-14       Impact factor: 2.953

3.  Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis.

Authors:  Leander Muheim; Andri Signorell; Stefan Markun; Corinne Chmiel; Stefan Neuner-Jehle; Eva Blozik; Pascale Ursprung; Thomas Rosemann; Oliver Senn
Journal:  Therap Adv Gastroenterol       Date:  2021-04-15       Impact factor: 4.409

4.  Prescribing patterns and economic costs of proton pump inhibitors in Colombia.

Authors:  Jorge Machado-Alba; Alejandra Fernández; Juan Daniel Castrillón; Carlos Felipe Campo; Luis Felipe Echeverri; Andrés Gaviria; Manuel José Londoño; Sergio Andrés Ochoa; Joaquín Octavio Ruíz
Journal:  Colomb Med (Cali)       Date:  2013-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.